Journal of Clinical Oncology 临床肿瘤· Vivek Subbiah·· 2026-10-14AI 评分50
澳大利亚对Nivolumab/Ipilimumab和Pembrolizumab的肿瘤无差别免疫疗法医保报销
Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement
AI 导读
澳大利亚医保政策将Nivolumab/Ipilimumab和Pembrolizumab纳入肿瘤无差别免疫疗法报销范围,适用于所有癌症类型。
来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org